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Background: Diagnosis of necrotizing enterocolitis (NEC), prevalent in premature infants, remains
challenging. Enterocyte damage in NEC can be assessed by intestinal fatty acid–binding protein
(I-FABP), with a sensitivity of 93% and a specificity of 90%. Numerous markers of inflammation are
known, such as serum amyloid A (SAA) and fecal calprotectin.
Purpose: The aim of the present study was to evaluate which combination of noninvasive measurement
of inflammatory markers and I-FABP improves the diagnostic accuracy in neonates suspected for NEC.
Methods: In 62 neonates with clinical suspicion of NEC (29 with final diagnosis of NEC), urinary I-
FABP, urinary SAA, and fecal calprotectin levels were determined quantitatively. Diagnostic accuracy
was calculated for the combinations I-FABP–SAA and I-FABP–fecal calprotectin, using a multi-
variable logistic regression model.
Results: The combination of SAA and I-FABP did not increase the diagnostic accuracy of I-FABP.
However, the combination of fecal calprotectin and I-FABP improved accuracy significantly. The
combination of urinary I-FABP and fecal calprotectin measurement produced a sensitivity of 94%, a
specificity of 79%, a positive likelihood ratio of 4.48, and a negative likelihood ratio of 0.08.
Conclusion: The combination of noninvasive measurement of I-FABP and fecal calprotectin seems
promising for diagnosing NEC at an early time point. Prospective analysis is required to confirm this finding
and to evaluate better treatment strategies based on noninvasive measurement of I-FABP and calprotectin.
© 2012 Elsevier Inc. Open access under the Elsevier OA license.⁎ Corresponding author. Department of Surgery, Maastricht University,
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x: +31 43 3884154.
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Open access under the Elsevier OA license.Necrotizing enterocolitis (NEC) is a severe neonatal
gastrointestinal disease with high morbidity and mortality
(20%-40%), characterized by inﬂammation and intestinal
1641Fecal calprotection and SAA combined with I-FABP in NECcell damage [1]. Diagnosis of NEC remains challenging
because the initial presentation is nonspeciﬁc and often hard
to distinguish from other gastrointestinal disorders and sepsis.
Although most laboratory tests and imaging techniques lack
diagnostic accuracy [2], measurement of intestinal fatty
acid–binding protein (I-FABP), a marker of intestinal cell
damage, has been reported to discriminate NEC from other
diseases with high sensitivity and speciﬁcity [3-5]. To deter-
mine the proper treatment strategy, it is of great importance to
differentiate NEC at an early time point. Noninvasive mea-
surement of diagnostic markers is preferred, to avoid the
risk of anemia caused by blood sampling. This study eval-
uated whether noninvasive measurement of the inﬂammatory
markers serum amyloid A (SAA) and fecal calprotectin could
improve the diagnostic accuracy of I-FABP in neonates with
suspected NEC.
Serum amyloid A is an acute-phase protein (11.5 kD),
synthesized by the liver upon induction by proinﬂammatory
cytokines [6]. Serum amyloid A was recently reported by Ng
and colleagues [7] to be a promising serum biomarker of
both NEC and sepsis in neonates. However, differentiation of
NEC from other diseases is important because several treat-
ment aspects are different, including surgical intervention in
cases of persistent NEC [8].
Calprotectin, a heterodimeric peptide (36 kD), is released
from the cytosol of neutrophils upon activation. Fecal cal-
protectin is a speciﬁc marker for neutrophil inﬁltrate in
bowel mucosa. In intestinal inﬂammation, calprotectin is
readily detectable in feces and plasma, making fecal calpro-
tectin a suitable marker for NEC [4,9,10].
We studied whether noninvasive measurement of the
inﬂammatory markers SAA (in urine) and calprotectin
(in feces) improves the diagnostic accuracy of urinary I-
FABP in neonates with gastrointestinal symptoms sus-
pected of NEC.1. Patients and methods
1.1. Patients and sample collection
Sixty-two consecutive patients with clinical suspicion of
NEC in the neonatal intensive care units at Maastricht
University Medical Center and Wilhelmina Children's
Hospital in Utrecht were studied between July 2005 and
August 2010. Data on 34 (13 NEC cases) neonates have been
previously published [4]. Suspected NEC was deﬁned as the
presence of abdominal distension causing sufﬁcient clinical
concern to require an abdominal radiograph and/or to stop
enteral feeding. Final diagnosis of NEC was made with the
current criterion standard of abdominal radiographic evi-
dence of pneumatosis intestinalis (Bell stage ≥II) [11].
Written informed consent was obtained from both parents,
and the study was conducted with approval from local
medical ethical committees and according to the revisedversion of the Declaration of Helsinki (October 2008, Seoul).
The principles of good clinical practice were followed during
this study.
Urine from all included neonates was obtained at the
time of clinical suspicion of NEC by placing a dental cotton
roll (Henry Schein, Almere, the Netherlands) in the diaper
of the neonate. The rolls containing urine were placed in a
sterile 5-mL syringe (Becton Dickinson, Oxford, UK), and
the urine was pressed into Micronic tubes (Micronic BV,
Lelystad, the Netherlands). Urine was stored at −20°C until
batch analysis. Stool samples were obtained and stored
immediately at −20°C until batch analysis. All laboratory
analyses were performed by 1 person after completion of
patient inclusion.
1.2. Power analysis
The number of patients needed for this study was calcu-
lated using the difference in SAA levels between controls and
neonates with NEC/sepsis [7] (α = .05, 1 − β = 0.95). This
produced a minimum number of 9 patients per group.
1.3. Urinary I-FABP measurement
Urinary I-FABP was measured using an in-house enzyme-
linked immunosorbent assay (ELISA) that selectively detects
human I-FABP (lower detection limit, 12.5 pg/mL). Values
are expressed as a ratio (in picograms per nanomole of crea-
tinine) of I-FABP (in picograms per milliliter) to creatinine
(in nanomoles per milliliter), to compensate for variations in
urine concentration (I-FABP/Cr).
1.4. Urinary SAA measurement
Urinary SAA was measured using a commercially avail-
able ELISA kit (lower detection limit, 15.0 ng/mL), kindly
provided by Hycult Biotechnology (Uden, the Netherlands).
Values are expressed as ratio (in picograms per nanomole
of creatinine) of SAA (in nanograms per milliliter) to
creatinine (in nanomoles per milliliter) ⁎ 1000, to compen-
sate for variations in urine concentration (SAA/Cr).
1.5. Fecal calprotectin measurement
After thawing of feces, 100 mg was weighed and 4.9 mL
extraction buffer (0.1 M Tris, 0.15 M NaCl, 1.0 M urea, 10
mM CaCl2·2H2O, 0.1 M citric acid, 0.5% bovine serum
albumin, pH 8.0) was added [12]. After 30 minutes of
shaking, 1 mL of suspension was centrifuged at 10,000 rpm
for 20 minutes at 4°C, and supernatant was aliquoted and
stored at −20°C. Calprotectin concentration was measured in
lysate using the commercially available calprotectin ELISA
(lower detection limit, 625 ng/mL), kindly provided by
Hycult Biotechnology. Fecal calprotectin concentration is
given in micrograms of calprotectin per gram of feces.
Table 2 Diagnoses associated with abdominal symptoms in
no-NEC group
CoNS sepsis 17
Gastrointestinal symptoms of unknown origin 10
Norovirus 2
Portal vein thrombosis 2
Rotavirus 1
Enterococcus faecalis sepsis 1
Enterobacter cloacae sepsis 1
Constipation 1
Hypomotility 1
Morbus Hirschsprung 1
Gastroschisis 1
Total 38⁎
CoNS, coagulase-negative staphylococcus.
⁎ Five patients had 2 diagnoses associatedwith abdominal symptoms.
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Normality was tested using the Kolmogorov-Smirnov
test. Mann-Whitney U test was used for between-group
comparisons for continuous data. Dichotomous variables
were compared using the Fisher exact test. All data are
presented as median and range.
To determine the accuracy of I-FABP combined with an
inﬂammatory marker in the diagnosis of NEC, 2 combina-
tions of markers were tested: I-FABP–SAA and I-FABP–
calprotectin. Predicted probabilities for the presence of NEC
were calculated for both combinations using logistic regres-
sion analysis and then plotted in receiver operating charac-
teristic (ROC) curves. Overall diagnostic accuracy of
I-FABP–SAA and I-FABP–calprotectin was represented
by the area under the curve (AUC). The best cutoff point of
predicted probabilities (P) was deﬁned as the cutoff point
with the maximum sum of sensitivity and speciﬁcity. To
calculate the linear function describing all combinations of
ideal cutoff values for I-FABP–SAA and I-FABP–calpro-
tectin in the diagnosis of NEC, the cutoff point (P) was used
in the following equation:
Ln(P/(1 − P)) = B0 + B1X1 + B2X2, in which B0 represents
the constant of the logistic regression analysis and B1 and B2
represent the logistic regression coefﬁcients of I-FABP and
SAA or I-FABP and calprotectin, respectively. By calculat-
ing coordinates of intersections with the x- and y-axes, the
linear functions describing the cutoff lines of I-FABP–SAA
and I-FABP–calprotectin could be determined.
Statistical analyses were performed using Prism 5.0 for
Windows (GraphPad Software Inc, San Diego, CA) and
SPSS 15.0 for Windows (SPSS Inc, Chicago, IL). Standards
for Reporting of Diagnostic Accuracy (STARD) statement
for reporting studies of diagnostic accuracy was used in this
study [13].2. Results
2.1. Patients
Sixty-two neonates were included, of whom 32 were
male. The median gestational age was 215 (175-289) days,
and the median birth weight was 1328 (585-3570) g.
Twenty-nine infants were diagnosed as having NEC (47%).
There were no signiﬁcant differences in gestational age,
birth weight, or sex between the groups (Table 1). FinalTable 1 Baseline characteristics
NEC (n = 29) No
Gestational age (d) 215 (184-268) 21
Birth weight (g) 1400 (860-1960) 127
Sex 11 M (38%) 21 M
Data are presented as median (range). M, male; F, female.diagnoses of premature infants without NEC are listed
in Table 2.
2.2. Single-marker analyses
2.2.1. Ratio of I-FABP to Cr
Median I-FABP/Cr levels in neonates with NEC were
signiﬁcantly higher compared with infants with other diseases
(11.4 [0.4-4878] and 1.2 [0.0-11.0] pg/nmol, respectively; P b
.001). An ideal cutoff value of 2.4 pg/nmol was found, with a
sensitivity of 79%, a speciﬁcity of 85%, a positive likelihood
ratio (LR+) of 5.23, and a negative likelihood ratio (LR−) of
0.24 (Fig. 1). The ROC curve yielded an AUC of 0.88 (95%
conﬁdence interval [CI], 0.80-0.97).
2.2.2. Ratio of SAA to Cr
Median SAA/Cr levels in neonates with NEC were sig-
niﬁcantly higher compared with infants with other diagnoses
(44.4 [9.3-31,127] and 21.5 [12.0-1469] pg/nmol, respec-
tively; P = .009). The AUC of the ROC curve was 0.70 (95%
CI, 0.56-0.83), with an ideal cutoff value of 42.2 pg/nmol
(sensitivity 52%, speciﬁcity 91%, LR+ 5.69, LR− 0.53).
2.2.3. Calprotectin
Stool samples were only available in 35 of 62 neonates
(16 with NEC [55%] and 19 with other ﬁnal diagnoses
[58%]). Median calprotectin levels in neonates with NEC
were signiﬁcantly higher compared with infants with other
diagnoses (402.2 [107.6-847.6] and 79.6 [1.0-625.1] μg/gNEC (n = 33) Total (N = 62) P
3 (175-289) 215 (175-289) .72
0 (585-3570) 1328 (585-3570) .67
(64%) 32 M (52%) .07
Fig. 1 Urinary I-FABP levels when NEC is clinically suspected
can accurately distinguish between neonates with ﬁnal diagnosis
of NEC and those with other ﬁnal diagnoses. A cutoff value of
2.4 pg/nmol creatinine is depicted by the dotted line.
Fig. 2 Combination of urinary I-FABP levels and urinary SAA
levels in neonates with ﬁnal diagnosis of NEC (squares) and those
with other ﬁnal diagnoses (triangles) when NEC is clinically
suspected. The ideal cutoff line for differentiating between NEC
and other diagnoses is depicted by the dotted line.
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was 0.82 (95% CI, 0.68-0.96), with an ideal cutoff value
of 286.3 μg/g feces (sensitivity 81%, speciﬁcity 79%, LR+
3.86, LR− 0.24).
2.3. Multiple-marker analyses
First, the combinations of I-FABP with SAA and I-FABP
with fecal calprotectin were analyzed by combining the
cutoff values found in the single-marker analyses. This im-
plies that a positive test result is obtained when both values
are above the cutoff value, that is, I-FABP greater than
2.4 pg/nmol and SAA greater than 42.2 pg/nmol. The com-
bination of I-FABP/Cr and SAA/Cr yielded the following:
sensitivity, 45%; speciﬁcity, 100%; LR+, inﬁnite; and LR−,
0.55 (Table 3). The combination of I-FABP/Cr and fecal
calprotectin produced the following: sensitivity, 63%;
speciﬁcity, 100%; LR+, inﬁnite; and LR−, 0.38 (Table 3).
In this analysis, no ROC curve can be calculated.
Second, a logistic regression analysis approach was used
to analyze the combinations of I-FABP with SAA and I-
FABP with fecal calprotectin.Table 3 Diagnostic markers
Marker Cutoff value Sensitivity
I-FABP/Cr 2.4 pg/nmol (creatinine) 79
SAA/Cr 42.2 pg/nmol (creatinine) 52
Calprotectin 286.3 μg/g (feces) 81
I-FABP/Cr + SAA/Cr a 2.4 + 42.2 45
I-FABP/Cr + calprotectin a 2.4 + 286.3 63
I-FABP/SAA b 83
I-FABP/Calprotectin c 94
a Combination of 2 markers in which a positive test result is obtained when
b [SAA/Cr(pg/nmol creatinine)] + 231.6 ⋅ [I-FABP/Cr(pg/nmol creatinine)]
c [Calprotectin (μg/g feces)] + 43.2 ⋅ [I-FABP/Cr(pg/nmol creatinine)] = 482.3.1. Combination of I-FABP/Cr and of SAA/Cr
When I-FABP/Cr and SAA/Cr were combined, a cutoff
line was calculated with a sensitivity of 83%, a speciﬁcity of
82%, an LR+ of 4.55, and an LR− of 0.21 (Fig. 2), thereby
not increasing diagnostic accuracy compared with measure-
ment of I-FABP/Cr. The cutoff line was described by the
linear function:
SAA = Cr pg= nmol creatinineð Þ½  + 231:6
 I−FABP = Cr pg = nmol creatinineð Þ½  = 862;
which means that a positive test is obtained when any
combination of SAA/Cr and I-FABP/Cr levels in this formula
results in a value more than 862. The AUC of the ROC curve
for discrimination of neonates with NEC from those with other
ﬁnal diagnoses was 0.88 (95% CI, 0.79-0.97).(%) Specificity (%) LR+ LR− AUC (95% CI)
85 5.23 0.24 0.88 (0.80-0.97)
91 5.69 0.53 0.70 (0.56-0.83)
79 3.86 0.24 0.82 (0.68-0.96)
100 Inﬁnite 0.55
100 Inﬁnite 0.38
82 4.55 0.21 0.88 (0.79-0.97)
79 4.48 0.08 0.95 (0.89-1.00)
both single-marker tests are positive.
= 862.
6.
Fig. 3 Combination of urinary I-FABP levels and fecal
calprotectin levels in neonates with ﬁnal diagnosis of NEC
(squares) and those with other ﬁnal diagnoses (triangles) when
NEC is clinically suspected. The ideal cutoff line for differentiating
between NEC and other diagnoses is depicted by the dotted line.
Note: stool samples were only available in 35 of 62 neonates.
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When I-FABP/Cr was combined with fecal calprotectin in
differentiating NEC from other ﬁnal diagnoses, a cutoff line
was calculated with a sensitivity of 94%, a speciﬁcity of
79%, an LR+ of 4.48, and an LR− of 0.08 (Fig. 3). The cutoff
line was described by the linear function:
Calprotectin lg= g fecesð Þ½  + 43:2
 I−FABP = Cr pg = nmol creatinineð Þ½  = 486;
which means that a positive test is obtained when any com-
bination of calprotectin and I-FABP levels in this formula
results in a value more than 486. The AUC of the ROC curve
was 0.95 (95% CI, 0.89-1.00).
Because the combination of I-FABP/Cr and fecal
calprotectin yielded the highest diagnostic accuracy, a multi-
variable logistic regression model was applied to evaluate
whether this combination of markers also could differentiate
Bell stage III from Bell stage II at the moment of clinical
suspicion of NEC. This resulted in an AUC of the ROC curve
of 0.55 (95% CI, 0.24-0.86; P = 0.75). These data show that
measurement of fecal calprotectin increases the diagnostic
accuracy of urinary I-FABP; however, it is not useful to
differentiate Bell stage III from Bell stage II.3. Discussion
This study aimed to assess whether noninvasive mea-
surement of the inﬂammatory markers SAA (in urine) and
calprotectin (in feces) improves the diagnostic accuracy of
the enterocyte damage marker I-FABP in neonates withgastrointestinal symptoms suspected of NEC. The data
show that measurement of fecal calprotectin but not SAA
improves the diagnostic accuracy of urinary I-FABP mea-
surement in diagnosing NEC.
In the current study, only noninvasive markers were
investigated because blood sampling in neonates should be
avoided [14] and because a clinical beneﬁt of the markers
has never been demonstrated. Classic parameters of infec-
tion (C-reactive protein, white blood cell count, platelets)
are, therefore, not presented here. A limitation of
noninvasive measurement of SAA is that little is known
about the plasma clearance of SAA. Although urinary SAA
levels were detected in a large part of the patients, further
research is needed to elucidate the renal clearance of SAA.
Cetinkaya et al [15] showed that plasma SAA levels were
elevated in neonates with NEC compared with neonates with
sepsis at themoment of diagnosis. In contrast, however, Eras et
al [16] reported higher plasma levels of SAA in children with
sepsis, compared with neonates with NEC. In our cohort,
measurement of urinary SAA alone was not useful as a
diagnostic marker for NEC owing to the low sensitivity. In a
recent study by Ng et al [7], SAA was reported to be a highly
speciﬁc marker of both NEC and sepsis in low-birth-weight
neonates. Importantly, the authors did not differentiate
between NEC and sepsis. Although initial medical treatment
is similar for both NEC and sepsis, resection of affected
bowel is essential in NEC when signs of perforation occur or
when symptoms do not improve on medical treatment. Here,
we aimed to distinguish NEC from other diagnoses including
sepsis at an early time point. Unfortunately, inclusion of
urinary SAA levels did not substantially improve the diag-
nostic accuracy of urinary I-FABP measurement in diagnos-
ing NEC. This might be caused by a lack of speciﬁcity of
SAA being a marker of generalized inﬂammation.
Next, this study aimed to include intestinal inﬂammation
and, more speciﬁcally, fecal calprotectin. It increased the
diagnostic accuracy of I-FABP measurement. Elevated
levels of fecal calprotectin in NEC are in line with several
studies [4,9,17]. In a previous study from our institute,
however, fecal calprotectin did not improve the diagnostic
accuracy of I-FABP [4]. This could have been a consequence
of the higher sensitivity and speciﬁcity of I-FABP than those
found in the current cohort.
The diagnostic accuracy improved when measurement of
fecal calprotectin was combined with I-FABP. The data
demonstrated a substantial increase in sensitivity and a
decrease in LR−, which is important in possibly lethal
diseases like NEC. When applying Bayes theorem [18,19]
with NEC prevalence of 47% in the studied cohort, a
negative test result of I-FABP alone produces a posttest
probability of 18% (95% CI, 10%-31%). This means that
18% of neonates with NEC are missed by the test (18% false
negatives). When both I-FABP and fecal calprotectin are
measured, the posttest probability of a negative test decreases
to 7% (95% CI, 2%-22%), which means that only 7% of
neonates with NEC are missed by the test. The posttest
1645Fecal calprotection and SAA combined with I-FABP in NECprobability when a positive test result is acquired is 82% (95%
CI, 67%-91%) for I-FABP and 80% (95% CI, 67%-89%) for
I-FABP combined with fecal calprotectin, which is com-
parable. The beneﬁt of the combination of I-FABP and cal-
protectin lies, thus, in a lower rate of missed NEC diagnoses.
The combination of 2 diagnostic markers allows us to
calculate a cutoff line instead of a single cutoff value because
we found that single markers or the combination of static
cutoff points was not clinically relevant enough to differ-
entiate NEC from other ﬁnal diagnoses in neonates suspected
for NEC. This cutoff line could be described as [calprotectin
(μg/g feces)] + 43.2 ⋅ [I-FABP/Cr (pg/nmol creatinine)] =
486, which means that a positive test is obtained when any
combination of fecal calprotectin and urinary I-FABP levels
in this formula results in a value more than 486. For clinical
application, a table or graph should be used when quick
decision making is required. Because feces was obtained in
only 35 (56%) of 62 neonates, the combined method was
only possible in 56% of the children. Further prospective
studies are needed to conﬁrm these results in a larger popu-
lation and to evaluate the effects of treatment strategies based
on calprotectin and I-FABP measurement.
This study shows that noninvasive measurement of SAA
adds little to the diagnostic accuracy of urinary I-FABP in
diagnosing NEC, whereas fecal calprotectin increases the
diagnostic accuracy in children who produce feces. The
combination of urinary I-FABP and fecal calprotectin may
be a promising noninvasive method for diagnosing NEC at
an early time point.References
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